Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(15):1113-1114; doi:10.1093/jnci/94.15.1113
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Liotta, L. A.
Right arrow Articles by Kohn, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liotta, L. A.
Right arrow Articles by Kohn, E. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 15, 1113-1114, August 7, 2002
© 2002 Oxford University Press

EDITORIAL

Stromal Therapy: The Next Step in Ovarian Cancer Treatment

Lance A. Liotta, Elise C. Kohn

Affiliation of authors: Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Correspondence to: Lance A. Liotta, M.D., Ph.D., Laboratory of Pathology, Center for Cancer Research, Bldg. 10, Rm. 2A33, 9000 Rockville Pike, Bethesda, MD 20892 (e-mail: liottal@mail.nih.gov).

The first 10% of the full text of this article appears below.

Among gynecologic cancers, ovarian cancer is the leading cause of death in the United States. Unfortunately, over two thirds of ovarian cancer cases are diagnosed at a late stage, when peritoneal dissemination of the ovarian cancer cells has already taken place (1). Understanding the molecular events that support the survival and implantation of disseminated ovarian cancer cells can provide urgently needed strategies for early detection, prevention, and intervention. It has long been suspected that cancer is a product of the tumor–host microenvironment . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed
Normalization of the Ovarian Cancer Microenvironment by SPARC
Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. J. Pelham, L. Rodgers, I. Hall, R. Lucito, K. C. Q. Nguyen, N. Navin, J. Hicks, D. Mu, S. Powers, M. Wigler, et al.
Identification of alterations in DNA copy number in host stromal cells during tumor progression
PNAS, December 26, 2006; 103(52): 19848 - 19853.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman
Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion
Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. M. Jacobsen, J. C. Harrell, P. Jedlicka, V. F. Borges, M. Varella-Garcia, and K. B. Horwitz
Spontaneous Fusion with, and Transformation of Mouse Stroma by, Malignant Human Breast Cancer Epithelium
Cancer Res., August 15, 2006; 66(16): 8274 - 8279.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Zou, K. S. Famulski, R. S. Parhar, E. Baitei, F. A. Al-Mohanna, N. R. Farid, and Y. Shi
Microarray Analysis of Metastasis-Associated Gene Expression Profiling in a Murine Model of Thyroid Carcinoma Pulmonary Metastasis: Identification of S100A4 (Mts1) Gene Overexpression as a Poor Prognostic Marker for Thyroid Carcinoma
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6146 - 6154.
[Abstract] [Full Text] [PDF]